Hola Borja. De acuerdo en moverlo en esta dirección. Busquemos que el proyecto sea **reconocible por sus actividades y gente** lo antes posible, y poder usarla para **generar colaboraciones y claridad en el ámbito de salud global y NTDs** .
- Hay que incorporar mucha información técnica que permita a otros investigadores conocer los detalles del proyecto. La web no es solo para público general.
- Asuntos a incluir:
- ## Objetivos generales y objetivos específicos del proyecto.
- *Overall goal*: Support the achievement of the [[WHO]] 2030 NTD Roadmap for [[STH]] and beyond
- *Project purpose*: Advance and accelerate an innovative pharmacological tool to support the elimination goals against [[STH]] species, specially those poorly responsive to current treatment regimens
- *The intervention*: A single tablet, [[Fixed-Dose Combination]] of Ivermectin and [[Albendazole]]
- *Specific objectives*:
- Provide a tool to support the achievement of the [[WHO]] Roadmap goals for [[STH]]
- Submission process of [[FDC]] to EMA & national agencies in [[Ghana]] and Kenya
- Safety and effectiveness tailored to policy makers for the control of [[STH]], including [[Strongyloides stercolaris]] and integration with other NTDs
- Acceptability, feasibility and adherence data added to the evidence package to support [[WHO]] guidance
- Develop a model for sustainable supply and costing
- Model the impact of different use cases and scenarios
- Pilot antihelmintic resistance surveillance based on genetic epidemiology
- ## Basic facts del proyecto
- En qué call de EDCTP (Global Health EDCTP3) ha salido
- Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026)
- Cuáles son los Work Packages y quién los lidera
- ## Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
- *Primary goal*: Safety (incidence of SAEs)
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
- *Sample size*: approx. 20k.
- *Target population*: School based
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
- *Countries*: [[Ghana]] and [[Kenya]]
- __Proposed acceptability and feasibility study__
- Palatability results confirm adecuacy of size, taste and smell
- Superior efficacy against T. trichiura confirms a comprehensive spectrum against STH
- Los papers más relevantes que salieran de los previos STOP
- ## Otros facts
- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Dosing strategies for Ivermectine are being revisited
- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies
- Acceptability and safety studies are underway
- The access plan is being developed
- Integration across programs (these results have implications beyond STH)
- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
- ## Investigadores principales de cada uno de los partners
- TODO Mandar un email y pedirles nombres para saber a quiénes citamos en la web y cómo quieren que los mostremos (Foto? enlace a LinkedIn? a página personal de su institución? crear una pequeña bio de cada uno en la web de stop2030?)
- ## Abstract del proyecto
- [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals.
The current proposal aims at accelerating the implementation of an innovative [[health]] technology, a [[Fixed-Dose Combination]] (FDC) tablet of co-formulated [[albendazole]] and ivermectin, with adequate safety and significantly superior efficacy against T. trichiura in a registrational randomized clinical trial. This trial is being conducted in Ethiopia, [[Kenya]] and Mozambique with the guidance of EMA and sponsored [[by]] [[EDCTP]] (STOP projects) with a Phase II trial completed and a Phase III currently recruiting.
This [[project]], [[STOP2030]], seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in [[Ghana]] and [[Kenya]], modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and [[WHO]] guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the [[FDC]] for [[STH]] control and elimination.
The Consortium assembled to execute the [[STOP2030]] proposal combines expertise in complementary fields [[from]] program assessment and implementation through Ministries of [[Health]] in sub Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained [[WHO]] prequalification for generic ivermectin #INFO
- La clave está en hacer énfasis en las cosas que ya se han hecho, en las que se están planeando/haciendo y en qué personas forman parte del proyecto. Las dos actividades esenciales son 2 ensayos clínicos en preparación. Uno es de seguridad/efectividad y el otro es de aceptabilidad/factibilidad/adherencia.
- Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation)
- Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo) https://www.ema.europa.eu/en/glossary/article-58-application https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/medicines-use-outside-european-union
- Primary objective: evaluate and compare safety of the [[FDC]] against [[albendazole]] alone via [[MDA]] in two study areas in [[Kenya]] and [[Ghana]]
- Project purpose: Advance and accelerate an innovative pharmacological tool to support the elimination goals against [[STH]] species, especially those poorly responsive to current treatment regimens
